Megan Sutcliffe

Megan Sutcliffe is a Research Fellow at the University of Manchester working within the Division of Immunology, Immunity to Infection and Respiratory Medicine at the Lydia Becker Institute of Immunology and Inflammation. She currently leads Helmsley Trust-funded research on expanded autologous Treg therapy for Crohn's disease patients in the Lord and Travis laboratory.

Her academic credentials include a Doctor of Philosophy from the University of Manchester (2019-2023) investigating CD4+ T-cell responses in inflammatory arthritis patients, and a First Class BSc in Pharmacology with Professional Placement from Newcastle University (2015-2019).

Dr. Sutcliffe's research centers on immunological mechanisms in autoimmune disorders, specializing in T-cell biology and therapeutic responses in Crohn's disease and rheumatoid arthritis. Her work integrates flow cytometry, bioinformatics, and clinical immunology to analyze treatment effects on immune cell populations, particularly regarding biologic drugs and TNF inhibitors.

Her publication trends reveal strong focus on personalized medicine approaches for rheumatic diseases, with recurring themes in TNF inhibitor pharmacogenetics, molecular health transitions in rheumatoid arthritis, and computational analysis of T-cell subset imbalances. These works bridge immunology, rheumatology, and bioinformatics to optimize treatment strategies.

Her scientific recognitions include:

• Research Project Prize from the Northern Institute for Cancer Research
• GSK Student Recognition of Excellence certificate

Dr. Sutcliffe collaborates extensively within the Lydia Becker Institute's immunology network, contributing to teams investigating immune therapies for inflammatory conditions. Her current Helmsley Trust project represents cutting-edge translational research in regulatory T-cell therapeutics for gastrointestinal autoimmunity.